ifinatamab deruxtecan + atezolizumab + carboplatin

A combination investigational regimen of **ifinatamab deruxtecan** (I-DXd), **atezolizumab**, and **carboplatin** used in clinical evaluation primarily for extensive-stage small cell lung cancer (ES-SCLC)[1][5]. - Ifinatamab deruxtecan is a B7-H3–directed antibody-drug conjugate (ADC); it consists of a humanized anti–B7-H3 IgG1 monoclonal antibody conjugated to a topoisomerase I inhibitor payload (DXd, an exatecan derivative) via a cleavable linker[3]. - Atezolizumab is an immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1), enhancing anti-tumor immune responses. - Carboplatin is a DNA-damaging platinum chemotherapy agent with cytotoxic properties. The combination is under investigation in early-phase trials for safety, dosage, and preliminary efficacy as first-line induction or maintenance for ES-SCLC[1][5].

Other names

I-DXd + atezolizumab + carboplatin